The Schall Law Firm, a national shareholder rights litigation firm, announced it is investigating claims on behalf of investors of Abivax S.A. regarding potential violations of federal securities laws. The investigation centers on whether Abivax issued false or misleading statements or failed to disclose pertinent information to investors. This scrutiny follows the release of results from the company's Phase 3 ABTECT trial for obefazimod, which revealed rare malignancy cases. Consequently, shares of Abivax fell sharply on June 2, 2026.

The firm is examining whether the company's disclosures regarding the trial results were accurate and timely. The Phase 3 ABTECT trial data is a critical component of Abivax's development pipeline for obefazimod. The emergence of rare malignancy cases in the trial results has raised concerns about the drug's safety profile and the company's reporting practices.

Investors who suffered losses in Abivax S.A. are encouraged to contact the Schall Law Firm to discuss their rights. The firm specializes in securities class action lawsuits and represents investors globally. Brian Schall of the Schall Law Firm is available to provide free consultations regarding the investigation.

Key Details of the Investigation

The Schall Law Firm represents investors around the world and focuses on securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under applicable law and rules of ethics.